Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
99mTc Sestamibi Scans in Differentiated Thyroid Cancer
NCT03065218Phase 4Terminated
- Sponsor
- MedStar Health Research Institute
- Start
- Oct 2016
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of technetium-99m sestamibi in differentiated thyroid cancer (DTC), sponsored by MedStar Health Research Institute. Started Oct 2016; status: terminated.
02
Drugs
technetium-99m sestamibi
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT03065218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03065218.